NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).

UnknownN/A

Sponsor: University Hospital, Clermont-Ferrand

Conditions: Multiple Sclerosis

Countries: France

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. It is characterized by different progressive forms with periods of flare-ups interspersed with phases of remission. MS manifests clinically with signs of multiple neurological dysfunctions as well as less specific symptoms such as fatigue, the prevalence of which is found to be high in these patients and is independently associated with an alteration in their quality of life. Recently, a non-invasive method for assessing maximal muscle oxidative capacity (mVO2) using optical measurement of muscle oxygenation (near-infrared spectroscopy, NIRS) has been described. Measuring tissue light absorption from a skin sensor facing a muscle, makes it possible to distinguish tissue concentrations of oxyhemoglobin (HbO2) and hemoglobin (Hb). The difference in absorbance of Hb and HbO2 corresponds to the balance of O2 supply and consumption in tissue capillaries, allowing calculation of a time constant (kNIRS, min-1) reflecting mitochondrial function. Current literature provides reference values in young healthy subjects and MS patients. This index could therefore constitute a particularly interesting non-invasive indicator of mitochondrial functioning, usable in the clinic.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with Multiple Sclerosis (MS) with a diagnosis established by MRI.
* Patients with a Kurtzke Expanded Disability Status Scale (EDSS) score \< 5.
* Body mass index (BMI) \< 30 Kg/m².
* Thickness of subcutaneous adipose tissue at the calf ≤ 20 mm.
* MS patients without neurological signs of flare-up since 1 month.
* MS patients who have not had any treatment modification during the last 2 months.
* Subjects affiliated to French health care system (for France).
* Volunteers who have given their written consent.

Exclusion Criteria:

* Patients suffering from progressive psychiatric pathologies (active psychosis, , etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.).
* People with poorly controlled or unstable cardiovascular disease.
* Major osteoarticular or neurological problems completely preventing the proper performance of the various tests.
* Persons under guardianship, curatorship, deprived of liberty or safeguarding justice.
* Pregnant or lactating women.

Locations (1)

Clermont-Ferrand, France